Wockhardt has received final approval from the FDA for Felodipine Extended-Release Tablets, the generic version of AstraZeneca‘s Plendil, a calcium channel blocker indicated for the treatment of hypertension as monotherapy or in combination with other antihypertensive agents.

Also, the company has received tentative approval to market Ziprasidone HCl, the generic version of Pfizer‘s Geodon, a serotonin and dopamine antagonist, indicated for the treatment of schizophrenia and as acute and maintenance treatment of manic or mixed episodes in bipolar disorder as monotherapy or as an adjunct to lithium or valproate.

Felodipine Extended-Release Tablets will be launched immediately in 2.5mg, 5mg, and 10mg dosage strength tablets. Ziprasidone HCl will be available on September 2, 2012 in 20mg, 40mg, 60mg, and 80mg dosage strength capsules.

For more information call (800) 346-6854 or visit www.wockhardtusa.com.